INDOLENT LYMPHOMAS


INDOLENT LYMPHOMAS

Poster number

Title

Submitting author

City and Country

107

Safety and Efficacy of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MAGNOLIA Phase 2 Study)

Judith Trotman

Concord, Australia

108

Long term outcomes of gastric MALT lymphoma treated with radiotherapy: a multi-centre retrospective study.

Clinton Smith

Randwick, Australia

109

Characteristics of Patients Achieving Complete or Partial Response (CR/PR) With Tazemetostat (TAZ) in Wild-Type Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Connie Batlevi

New York, NY, USA

110

Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA

Guillaume Cartron

Montpellier, France

111

Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): primary analysis of a Phase 1b/2 trial

Rajat Bannerji

New Brunswick, NJ, USA

112

CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

Pier Luigi Zinzani

Bologna, Italy

113

Zandelisib, a PI3Kδ Inhibitor on Intermittent Schedule (IS) in Follicular Lymphoma Patients who Progressed within 24 Months of First-Line Chemoimunotherapy (POD24)

John Pagel

Seattle, WA, USA

114

Outcomes in later-lines of therapy for relapsed/refractory follicular lymphoma: Results from the international SCHOLAR-5 study

Paola Ghione

New York, NY, USA

115

Outcome of 133 patients with follicular lymphoma (FL) progressing before 24 months (POD24) after immunochemotherapy: a GELTAMO study.

Ana Muntañola

Barcelona, Spain

116

Bendamustine-Rituximab compared to Rituximab-CHOP/CVP for treatment of patients with indolent lymphoma in Ontario: a population-based study.

Adam Suleman

Toronto, Canada

117

Maintenance therapy after R-bendamustine vs R‐CHOP in first‐line treatment of low-grade follicular lymphoma: a multicentre, retrospective GELTAMO Study

Mariana Bastos-Oreiro

Madrid, Spain

118

Obinutuzumab can be administered as a 90-minute short-duration infusion (SDI) in patients with previously untreated follicular lymphoma: GAZELLE end of induction analysis

Kai Hübel

Köln, Germany

119

UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD-DRIVEN IMMUNOTHERAPY IN EARLY-STAGE FOLLICULAR LYMPHOMA

Alessandro Pulsoni

Roma, Italy

120

Clinical outcomes and the role of observation in early-stage follicular lymphoma

Fushen Sha

New York, NY, USA

121

Early metabolic response in Follicular lymphoma: a subset analysis of the FOLL12 trial by the Fondazione Italiana Linfomi (FIL).

Stefano Luminari

Reggio Emilia, Italy

122

The role of FDG-PET/CT and bone marrow biopsy in detecting bone marrow involvement in the initial staging of follicular lymphoma: an analysis of accuracy and prognostic impact.

Laura Reguilón Gallego

Murcia, Spain

123

Clinical utility of interim CT scans in patients receiving chemoimmunotherapy for first line treatment of follicular lymphoma

Farheen Manji

Toronto, Canada

125

Evaluation of four prognostic indexes in first line follicular lymphoma treated with immunochemotherapy.

Antonio Salar

Barcelona, Spain

126

ANALYSIS OF EZH2 MUTATIONS IN SOLID AND LIQUID BIOPSY AND ITS ROLE AS PREDICTIVE BIOMARKER FOR CHEMOTHERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA

Mariana Bastos Oreiro

Madrid, Spain